Mission Pharmacal Company

Mobile Version

Read the bacterial vaginosis press releaseTINDAMAX® (tinidazole)

THE FIRST NEW ORAL TREATMENT
FOR BACTERIAL VAGINOSIS IN A DECADE

Tindamax® (tinidazole) has been approved by the FDA for the treatment of bacterial vaginosis (BV), the most common vaginal infection among women of childbearing age in the United States.

Details:
Press Release»
About Bacterial Vaginosis»
About Tindamax»

For six decades and three generations,
Mission Pharmacal has dared to make a difference.

The pioneering spirit has long been a prevailing characteristic of Mission Pharmacal. It was the catalyst that inspired H.N. (Wally) Walsdorf, a pharmacist and our founder, to embark on his mission: To develop and manufacture pharmaceuticals with raw materials of superior quality to ensure the very best and most effective product. In 1946, Wally wanted to make a difference. Today, Mission Pharmacal is the guardian of that heritage. Continue»

Recent Press Releases

12/05/2007
Mission Pharmacal Sells Gold Standard Kidney Stone Diagnostic Tests to Quest Diagnostics
8/30/2007
Mission Pharmacal Sells Citracal® Calcium Brand to Bayer HealthCare
7/31/2007
New Study Finds Tindamax® To Be Effective, Well-Tolerated Treatment for Bacterial Vaginosis
Tindamax®
Now approved for the treatment of bacterial vaginosis, the most common vaginal infection among women of childbearing age in the United States.  
CitraNatal product logos  
Outsource Manufacturing
Whether your product is classified as a nutritional, OTC, or Rx product we can provide total turnkey service.